Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-PROTKT: Vicadrostat + empagliflozin in type 2 diabetes, hypertension, and cardiovascular disease
jRCT2031250347Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), hypertension (HTN), cardiac morbidity and 2 more comparing Vicadrostat + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Time to first event of cardiovascular death or heart failure event. Started Oct 2025; status: recruiting.
02
Drugs
vicadrostat
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)cardiac morbidityheart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031250347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250347.